Figure 5.
Influence of maternal viral load before or after lamivudine treatment on hepatitis B virus mother-to-child transmission as indicated by serum hepatitis B surface antigen or hepatitis B virus DNA of newborns within 24 h after birth. Vertical line indicates no difference between compared treatments. Horizontal lines show 95% CIs. Squares indicate point estimates, and the size of the squares indicates the weight of each study in the meta-analysis. CI: Confidence interval; HBV: Hepatitis B virus; M-H random: Mantel-Haenszel random-effects model; RR: Risk ratio; HBsAg: Hepatitis B surface antigen.
